Avalon Capital Management Takes Position in Amgen Inc. $AMGN

Avalon Capital Management acquired a new position in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 28,909 shares of the medical research company’s stock, valued at approximately $9,462,000. Amgen accounts for 2.3% of Avalon Capital Management’s investment portfolio, making the stock its 12th largest position.

Several other hedge funds have also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of Amgen during the fourth quarter worth approximately $2,164,162,000. Capital World Investors boosted its stake in Amgen by 11.5% in the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after buying an additional 1,935,876 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares during the last quarter. Vanguard Group Inc. grew its position in Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after acquiring an additional 961,975 shares during the last quarter. Finally, National Bank of Canada FI increased its stake in shares of Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after buying an additional 863,216 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 3.0%

Shares of AMGN stock opened at $338.22 on Thursday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The stock has a market cap of $182.54 billion, a price-to-earnings ratio of 23.54, a PEG ratio of 3.29 and a beta of 0.42. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29. The firm’s 50-day moving average is $341.49 and its 200-day moving average is $345.38.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts predict that Amgen Inc. will post 22.38 EPS for the current year.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AMGN. UBS Group boosted their price objective on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Guggenheim decreased their price target on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a report on Monday, May 4th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Barclays began coverage on shares of Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 target price on the stock. Finally, Argus lowered their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Amgen has an average rating of “Hold” and an average target price of $355.19.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen secured European Commission approval for Imdylltra in a lung cancer indication, strengthening the drug’s commercial outlook and validating its clinical profile. EC approval for Amgen’s Imdylltra
• Positive Sentiment: Amgen also announced new data presentations at the EULAR 2026 conference for rare autoimmune and inflammatory diseases, including longer-term safety and efficacy data for UPLIZNA and TAVNEOS, which may support these products’ market positioning. AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
• Positive Sentiment: Another report highlighted analyst commentary on Amgen, which can reinforce investor confidence if recent updates are viewed favorably by the market. Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Thermo Fisher (TMO)
• Neutral Sentiment: A feature story noted Amgen’s early adoption of AI under CEO Bob Bradway, underscoring the company’s push to improve research productivity, though it is not an immediate financial catalyst. The CEO who loves AI autodidacts — and desperately needs his experts

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.